Irish drugmaker Elan and US partner Biogen Idec announced today that Britain's cost-effectiveness health watchdog had recommended their Tysabri drug to treat a severe form of multiple sclerosis.
The firms said the National Institute for Health and Clinical Excellence had recommended Tysabri as a treatment for highly active relapsing remitting multiple sclerosis.
